Glenmark signs up marketing deal with MyerZall Labs

27 Oct 2007

1
Mumbai: Glenmark Pharmaceuticals has inked a decade long marketing and distribution agreement with MeyerZall Laboratories.

Formalised through Glenmark Pharmaceuticals South Africa, the deal will help the expansion of the company''s product portfolio in the topical dermatology segment, and covers therapeutic areas such as psoriasis, fungal infections of the skin and inflammation.

Consequently, products with patented delivery systems such as Linotar Gel1, Covarex and Athru-Derm will come under Glenmark''s wing, alongside its existing range of derma products that spans Synalar, Synalar-C, Synalar-N and Naseptin.

Glenmark had acquired Bouwer Bartlett Pty Ltd in December 2005, a South African sales and marketing company. The acquisition was implemented through Glenmark''s wholly-owned Swiss subsidiary.

According to Glenmark, it is one of the leading players in the Indian dermatology segment, with its Candid B featuring among the top 300 pharmaceutical products in the country.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more